Sequential Phase II Study of the Anti-Idiotype Monoclonal Antibody Vaccine CeaVac and TriAb in Patients With Minimal Metastatic Colorectal Cancer

NCT00033748 Phase 2 COMPLETED

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have colorectal cancer that has spread to the liver.

Details

Lead sponsor	Alliance for Clinical Trials in Oncology
Phase	Phase 2
Status	COMPLETED
Enrolment	56
Start date	2001-12
Completion	2010-06

Conditions

• Colorectal Cancer
• Metastatic Cancer

Interventions

• monoclonal antibody 11D10 anti-idiotype
• monoclonal antibody 3H1 Alu Gel

Primary outcomes

• Recurrence free survival — 2 years

Countries

United States